Investors
This section contains information about Orion as an investment.
Stock exchange releases
- 2/12/2026 The Board of Directors of Orion Corporation decided on a new plan period for the Long-term Incentive program for the company’s key persons
- 2/12/2026 Notice to the Annual General Meeting of Orion Corporation
- 2/12/2026 Orion Group Financial Statement Release January–December 2025
- 2/3/2026 62,752 Orion Corporation A shares converted into B shares
Press releases
- 1/30/2026 Orion publishes Financial Statement Release for 2025 and holds a webcast on 12 February 2026
- 1/8/2026 Orion Pharma announces the initiation of TEADES Phase 2 trial of ODM-212 in Malignant Pleural Mesothelioma (MPM) and Epithelioid Hemangioendothelioma (EHE)
- 11/14/2025 Orion receives award for international growth from the President of the Republic of Finland
- 10/23/2025 Orion and Abzena announce exclusive commercial license for Abzena’s antibody